Clinical Report: OI Therapy Raised BMD, Not Fracture Benefit
Overview
The TOPaZ trial found that teriparatide followed by zoledronic acid improved bone mineral density (BMD) in adults with osteogenesis imperfecta but did not significantly reduce fracture incidence compared to standard care.
Background
Osteogenesis imperfecta (OI) is a genetic disorder characterized by fragile bones and increased fracture risk. Effective management of OI often focuses on improving bone density and reducing fracture rates. The role of pharmacologic therapies, such as teriparatide and zoledronic acid, in achieving these goals remains an important area of investigation.
Data Highlights
| Group | Imaging-confirmed Fractures | Bone Mineral Density (BMD) |
|---|---|---|
| Teriparatide + Zoledronic Acid | 65/176 (36.9%) | Higher at lumbar spine and hip |
| Standard Care | 63/173 (36.4%) | Lower than intervention group |
Key Findings
Patient-reported fractures were more common than imaging-confirmed fractures, with no statistically significant difference between groups.Clinical Implications
The findings suggest that while teriparatide and zoledronic acid can enhance bone mineral density in adults with OI, they may not effectively reduce fracture risk. Clinicians should consider these results when discussing treatment options with patients and managing expectations regarding fracture prevention.
Conclusion
The TOPaZ trial highlights the complexity of treating osteogenesis imperfecta, demonstrating improvements in bone density without corresponding reductions in fracture rates.
Related Resources & Content
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial | JAMA, 2026 -- JAMA Network
- Osteogenesis imperfecta - Symptoms, diagnosis and treatment | BMJ Best Practice US
- Knee Surgery, Sports Traumatology, Arthroscopy — Zoledronic acid demonstrates superior efficacy compared to ibandronic acid for managing symptomatic bone marrow lesions in the knee
- The Journal of Clinical Endocrinology & Metabolism — Bone Material Strength Index Is Low in Patients With Cushing's Syndrome Even After Long-term Remission
- Clinical Rheumatology — Lower odds of prevalent vertebral fractures with b/tsDMARD use among rheumatoid arthritis patients in clinical remission: a retrospective observational study
- The Journal of Clinical Endocrinology & Metabolism — Eldecalcitol Supplementation with Risedronate Mitigates Bone Density Loss Induced by Aromatase Inhibitors in Postmenopausal Women with Breast Cancer
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network
- Osteogenesis imperfecta - Symptoms, diagnosis and treatment | BMJ Best Practice US
- Guidelines – ERN BOND
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
